Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Comment by HepburnMcRaeon Dec 01, 2020 7:50pm
319 Views
Post# 32015198

RE:Private Placement and share price

RE:Private Placement and share priceYes. A Private Placement allows "Accredited Investors" to acquire shares at a price speculated to be better than on open market.
An  Accredited Investor is quite simply someone with a lot of money to invest. Rather than buy a zillion shares retail they can buy a zillion shares thru private placement at a price usually anticipated to be below market value. An astute investor would not buy shares in PP at .01 anticipating the stock price will be below .01. The fact that they are offering PP at .01 means they anticipate the stock to be higher than .01 on PP closing otherwise why would anyone bother buying into the PP?
The stock price doesn't effect the pp closing. The more the stock goes up the more interest there will be in the PP though.


<< Previous
Bullboard Posts
Next >>